HCP
PCRX icon

Hexagon Capital Partners’s Pacira BioSciences PCRX Stock Holding History

Hexagon Capital Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42
Closed -$1.62K – 1489
2022
Q4 		$1.62K Buy
42
+37
+740% +$1.8K ﹤0.01% 1124
2022
Q3 		$0 Buy
+5
New +$278 ﹤0.01% 1399

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Hexagon Capital Partners's PCRX Position: Q1 2023 in Review

Hexagon Capital Partners sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 42 shares — an estimated $1.62K sold.

Hexagon Capital Partners first reported a position in PCRX in Q3 2022 and held it in 2 quarters. The position peaked at $1.62K in Q4 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

  • Hexagon Capital Partners reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
  • Hexagon Capital Partners sold 42 Pacira BioSciences shares in Q1 2023, an estimated $1.62K.
  • Hexagon Capital Partners first reported a position in Pacira BioSciences in Q3 2022 and held it in 2 quarters.
  • Hexagon Capital Partners's Pacira BioSciences position peaked at $1.62K in Q4 2022.
  • 267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Hexagon Capital Partners's 13F filing for Q1 2023, filed 24 Apr 2023.